ANYONE IN THIS TRIAL: Prothena PASADENA P... - Cure Parkinson's

Cure Parkinson's

26,568 members27,876 posts

ANYONE IN THIS TRIAL: Prothena PASADENA Phase 2 trial? Love to hear what you think - some say most promising PD trial.

p-oui profile image
11 Replies

This trial will enroll 300 people and the Pharma company, ROCHE, is investing $600 Million into this trial. Trial is for those who have been diagnosed with PD within the last two years but are not yet taking dopaminergic medication. They can be on a monoamine oxidase-B inhibitor such as rasagiline (azilect) or selegiline.

For the first year, one-third of the cohort will receive placebo and one-third a low dose of antibody, 1,500 mg. The remainder will take a high dose, which will vary by body weight—3,500 mg for people under 65 kg; 4,500 for those 65 kg or heavier. The high dose is roughly equivalent to the highest dose tested in Phase 1, 60 mg/kg.

Is anyone on HU in this trial? If so, would be very helpful to hear about your experience!

For more information on the Prothena Phase 2 clinical study of PRX002/RG7935 in patients with Parkinson's disease, visit clinicaltrials.gov and search NCT #03100149.

Written by
p-oui profile image
p-oui
To view profiles and participate in discussions please or .
Read more about...
11 Replies
Juliegrace profile image
Juliegrace

Can you supply a link to the study?

jeffreyn profile image
jeffreyn in reply toJuliegrace

Here is the link:

clinicaltrials.gov/ct2/show...

p-oui profile image
p-oui in reply tojeffreyn

Thank you Jeffreyn, here is another link to share with those interested in clinical trials scienceofparkinsons.com/201...

p-oui profile image
p-oui in reply toJuliegrace

a general link that is good: scienceofparkinsons.com/201...

p-oui profile image
p-oui in reply toJuliegrace

Just another point of interest: globenewswire.com/news-rele...

rebtar profile image
rebtar

I'm in the process of seeing if i qualify. Hopefully know more next week.

p-oui profile image
p-oui in reply torebtar

rebtar, I am also getting screened and should know more next week also. Do you know anyone who is enrolled? I've researched this a great deal but there is still a lot of risk. Key questions in my mind:

What value - if any - does ASN contribute?

Can they target good vs bad ASN vs just blasting all ASN clumps?

What are long term effects of eliminating ASN clumps?

Finally, the safety trial (phase 1) was small, short and saw no symptom improvement

Why would I do it? I am still early phase (as defined by this study) and it's a sure thing in terms of reducing ASN clumps which may be the only way to slow progression.

rebtar profile image
rebtar

No, i don't know anyone who is enrolled. If you have links to the research you've done i'd be interested.

p-oui profile image
p-oui in reply torebtar

scienceofparkinsons.com/201.... I list a few more above

jeffreyn profile image
jeffreyn

This article from AlzForum discusses the recently-published PRX002 Phase 1b results.

alzforum.org/news/research-...

jeffreyn profile image
jeffreyn in reply tojeffreyn

This post on the SoPD blog covers the recently-released PRX002 Phase 1b results (and includes a lot of background information).

scienceofparkinsons.com/201...

Not what you're looking for?

You may also like...

Is anyone taking Mirapex / pramipexole? Based on this early phase trial with good results I wanted to try it.

P2B001 combines low-dose pramipexole and rasagiline, sold under the brand names Mirapex and...
p-oui profile image

Oral ANVS401 Improves Patients’ Motor Skills in Phase 2 Trial

' Once-a-day treatment with oral ANVS401 was found to significantly improve motor skills among...

Back to Melatonin - Dosing?

I won't go as deep as Art does on Melatonin, but am picking up on a point Art makes often: Dosing!...

Mucuna Pruriens in Parkinson's disease, dosages and effects, A double-blind, randomized, controlled, crossover human study (2017)

Mucuna pruriens in Parkinson disease. A double-blind, randomized, controlled, crossover study...
Greenday profile image

Hot off the press. Randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease.

Open access Published: 28 November 2023 Abstract Nicotinamide adenine dinucleotide (NAD)...